Showing 101-110 of 5352 results for "".
Viewpoints: A New Roadmap in Eczema Care
https://practicaldermatology.com/topics/practice-management/viewpoints-a-new-roadmap-in-eczema-care/21144/New strategies in clinical care and advocacy will be essential in this emerging era of eczema management.EHR User Series—Part IV
https://practicaldermatology.com/topics/practice-management/ehr-user-seriespart-iv/21494/The final entry in a Q&A series with clinicians about their experience and broader impressions of EHRs in dermatology.Your EHR Server: Cloud vs. Hosted
https://practicaldermatology.com/topics/practice-management/your-ehr-server-cloud-vs-hosted/21606/While EHRs are shifting to cloud-based servers, clinicians should consider how each model suits their individual needs.Clinical Focus: Acne: Back in the Spotlight: Effective Options for Truncal Acne
https://practicaldermatology.com/topics/general-topics/back-in-the-spotlight-effective-options-for-truncal-acne/22031/Data suggest that patients may be unlikely to report truncal acne. Clinicians must assess chest and back involvement and be prepared to offer effective treatments.Pearls for the Diagnosis and Management of Eyelid and Lip Dermatitis
https://practicaldermatology.com/topics/general-topics/PD1009_06-php/20366/With sensitivity to diagnostic clues and initiation of appropriate therapeutic strategies, clinicians can eliminate irritant dermatitis of the lips and eyelids.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvDermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinKey Components of an Effective Strategic Plan
https://practicaldermatology.com/topics/practice-management/key-components-of-an-effective-strategic-plan/23933/A number of actionable steps can effectively and efficiently ensure that your practice stays on track.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.Unplugged: Cutting-Edge Aesthetic Medicine
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/unplugged-cutting-edge-aesthetic-medicine/20142/Jeanine Downie, MD shares pearls from her presentation in the Unplugged session she co-chaired with José Montes, MD. She discusses some of the latest tightening devices for the face, neck, and body, including EmFace, Zaffiro, and Sofwave. Plus, she reviews topics presented by colleagues throughout t